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Non-enzymatic glycation and altered renal structure and function in the
diabetic rat. Renal functional parameters including creatinine clearance,
urinary albumin excretion, basement membrane thickening, and levels
of non-enzymatic glycation of glomerular basement membrane were
studied in rats rendered diabetic with streptozotocin. Diabetic animals
had elevated, glycated hemoglobin levels (P < 0.05), increased creati-
nine clearance, and urinary albumin excretion rates (P < 0.05) as
compared to insulin treated diabetic (euglycemic), age-matched, and
streptozotocin non-diabetic animals. The level of non-enzymatic glyca-
tion of glomerular basement membrane was significantly elevated (P <
0.05) in the diabetic animals as well, with the level of non-enzymatic
glycation of all animals, correlating (P < 0.05) to the average blood
glucose level of each animal. Despite changes in functional parameters,
and increased levels of non-enzymatic glycation between the diabetic
and euglycemic animals, there was no difference in glomerular base-
ment membrane thickness between the two groups. However, there
was a difference between all diabetic euglycemics and the age—matched
control animals. We hypothesize that increased glycation of glomerular
basement membrane may alter renal function, possibly by affecting the
net charge of the glomerular filtration barrier. However, glomerular
basement membrane thickening per se does not affect the functional
changes which have been observed, thus casting doubt upon its role in
the development of diabetic nephropathy.
Diabetic nephropathy is one of the most common secondary
complications of diabetes. It has been shown that 40% of
patients with diabetes eventually develop nephropathy with
increased proteinuria and decreased glomerular filtration rate
(GFR) [1]. The etiology of diabetic nephropathy is not known,
but one hypothesis suggests that the increased blood glucose
levels encountered in diabetes in some way may lead to renal
changes [2].
An increase in blood glucose has been shown to result in
increased levels of non-enzymatic glycation [3]. Non-enzymatic
glycation is a common post-translational modification which
has been shown to occur for many proteins [4, 5]. It is a result
of direct chemical reaction between reducing sugars and pri-
mary amino groups of proteins, ultimately resulting, via Ama-
don rearrangement, in the formation of a stable ketoamine
derivative [61. The reaction is glucose dependent and is in-
creased in hyperglycemic situations. Non-enzymatic glycation
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has been shown to alter the structure and function of many
proteins, both in vitro and in vivo [5, 7, 8].
The hyperglycemia found in diabetes has been shown to
result in increased non-enzymatic glycation of proteins. This
may precipitate changes in the composition and synthesis of
glomerular basement membrane [9, 10], ultimately leading to
functional and morphological changes in the kidney. The func-
tional changes that occur early on in diabetic nephropathy
include an increase in the GFR [11] and development of
microalbuminuria [12], notably in poorly controlled diabetic
subjects. The specific role that non-enzymatic glycation plays in
these changes in renal function remains unclear; however, it
may alter membrane permeability, causing a gradual loss of
selective filtration resulting in non-selective proteinuria [131.
Previous morphological studies have shown an increase in
glomerular basement membrane thickening in human diabetics
over that of normal individuals [14]. Others, however, have
reported poor correlation between functional changes, such as
GFR and microalbuminuria, and basement membrane thickness
in long—term diabetic subjects [15—17]. In experimentally in-
duced diabetes, Cohen et al [18] demonstrated an increase in
non-enzymatic glycation of glomerular basement membrane;
however, these authors did not investigate its relationship to
morphological and functional changes in the kidney.
In view of the conflicting data cited in the aforementioned
clinical studies and paucity in the studies on experimental
animals, the present investigation was designed to examine the
relationship between hyperglycemia, non-enzymatic glycation,
and renal structure and function concurrently in experimentally
induced diabetic rats.
Methods
Animals
A total of 34 male, Sprague—Dawley rats (300 to 350 g) were
injected intraperitoneally with a single injection of streptozo-
tocin (65 mg/kg) dissolved in cold citrate buffer (pH 4.5).
Hyperglycemia (blood glucose greater than 20 mmollliter) and
glycosuria were present three days after injection in 24 animals,
while the other 10 remained euglycemic (streptozotocin injected
non-diabetic group). The 24 "diabetic" animals were divided
into two groups. The diabetic euglycemic group (N = 12) were
maintained at a blood glucose level of 4.5 to 6.5 mmollliter by
daily injection of protamine—zinc insulin (Connaught Laborato-
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ries, Willowdale, Ontario, Canada). The dosage ranged from 2
to 14 units/day depending on the animal and was adjusted
according to bi-weekly blood glucose monitoring. The remain-
ing animals (N = 12) were treated in a similar manner, with the
exception that the blood glucose levels were maintained at 19 to
22 mmol/liter (diabetic hyperglycemic group). A fourth group
consisted of age—matched rats (N = 10) injected only with the
citrate buffer. These animals served as a control group. The
animals from all four groups were housed in individual cages for
5 months with food (Wayne F6 rodent blox) and water available
ad libitum. There was a 40% mortality of animals from all
groups during the duration of the study; the total number of
surviving animals at the end of the study period being 26,
Twenty—four—hour urine collections and blood samples were
obtained for analysis of creatinine clearance, glycated hemo-
globin, and urinary albumin at time 0, 2, and 5 months of the
study. Body weights of all the animals were recorded weekly
for the duration of the study and kidney weights were measured
at sacrifice.
Functional studies
Blood glucose was monitored bi-weekly in whole blood
obtained by tail bleed and quantitated using Dextrosticks and
read on a glucometer (Ames Division, Miles Laboratories Ltd.,
Rexdale, Ontario, Canada).
Glycated hemoglobin was measured by affinity chromatogra-
phy using a commerically available kit (Glyco-Test, Pierce
Chemical Co., Rockford, Illinois, USA), as previously de-
scribed [19]. The between run coefficient of variation for this
method was less than 10%.
Renal function was evaluated by creatinine clearance, which
was expressed in relation to body weight at 0, 2, and 5 months
of study. At five months, the creatinine clearance was ex-
pressed in relation to renal weight. Serum and urine creatinine
was measured by an autoanalyzer (Beckman Astra, Beckman
Inc., Brea, California, USA) using an alkaline picrate method
[20].
Urinary albumin was measured by radioimmunoassay by
modification of Miles et at and Woo et at [21, 22]. Rabbit anti-rat
albumin was obtained from National Biological Laboratories,
Winnipeg, Manitoba, Canada. Briefly, the antibody was raised
to globulin—free rat albumin (Sigma Chemical Co., St. Louis,
Missouri, USA; A4538). Iodine 125 bovine serum albumin
(NEN products, Dupont Canada, Inc., Lachine, Quebec, Can-
ada) was used as the tracer. Two hundred d of sample,
standard, or control was pipetted into 12 X 75 mm glass tubes.
One hundred M' of antibody, and 100 of tracer (0.2 Ci/ml) was
added. The mixture was incubated for two hours at room
temperature; and the bound fraction collected after precipita-
tion with 25% (wt/vol) polyethylene glycol (PEG) and centrifu-
gation. The RIA showed good recovery, parallelism, and sen-
sitivity (2 g/ml). The intra- and inter-assay coefficient of
variations were 3.2% and 6.2%, respectively. The results were
expressed in pg/hr.
Procurement of tissues
After five months of study, the animals were anesthetized
with sodium pentobarbital and blood drawn via cardiac punc-
ture for subsequent analysis of creatinine, glycated hemoglobin,
and blood glucose. Kidneys were rapidly excised, a slice of the
left kidney obtained for electron microscopy, and the remaining
tissue placed in cold isotonic saline for subsequent isolation of
the glomeruli.
Isolation of glomerular basement membrane
Glomeruli were isolated from renal cortex by differential
sieving through a series of nylon meshes according to Cohen
and Carlson [23], with the material on the 88 im and 105 m
screens collected as glomeruli. The basement membrane was
isolated by osmotic lysis and sequential detergent extraction
using 3% triton-X 100, deoxynuclease digestion, and sodium
desoxycholate; as described by Carlson et al [24]. Although the
amount of glomerular basement membrane isolated from each
animal was not determined in this study, it was previously
determined that approximately two mg of protein (as measured
by Lowry et al [251) was isolated per kidney, and was found to
exhibit the characteristic electrophoretic pattern of pepsin
digested type IV collagen as shown by previous investigators
[91.
Measurement of non-enzymatic glycation
The level of non-enzymatic glycation was assayed by borohy-
dride reduction and boronic acid affinity chromatography as
previously described [26—28]. Two mg of lyophylized basement
membrane was suspended in 200 d of water, followed by the
addition of 200 d of 0.10 N NaOH containing 625 pCi of
tritiated sodium borohydride (Amersham Canada LTD.,
Oakville, Ontario, Canada; specific activity 500 mCi/mmol) and
12.5 mg of unlabelled sodium borohydride. Reduction was
carried out for 90 minutes on ice in a fumehood, and was
stopped by the addition of 4 ml of 10% (wt/vol) trichioroacetic
acid (TCA). The reduced basement membrane was washed a
number of times with 10% TCA, followed by centrifugation and
aspiration of the supernatant. The washed pellet was hydro-
lyzed with 1.5 ml of 6 M HCI for 16 hours at 110°C, in sealed
screw—top tubes. The pH was adjusted to 8.5 by the addition of
concentrated NaOH. The amino acid concentration of the
hydrolysate was determined by the ninhydrin procedure [291
using a standard curve produced with known concentrations of
leucine. Results were expressed in leucine equivalents. Four
hundred M1 of the hydrolysate was also loaded onto a m-
aminophenylboronic acid column (Glycogel GSP columns, Isolab
Inc., Akron, Ohio, USA) and washed with 15 ml of 50 mr'vi
(Na)2HPO4. The bound amino acids were removed by the
addition of 2 ml of 0.10 M HC1. One ml of the eluate was
counted on a LKB 12-19 scintillation counter (LKB. Turko,
Finland) using a quench—corrected counting program. The
results were expressed as CPM/mol leucine equivalents.
Morphological studies
Small pieces of kidney cortex were fixed in 3% glutaralde-
hyde in 0.1 M buffer (pH = 7.4) for 2 hours at 4°C. Tissues were
rinsed for 24 hours at 4°C in 0.1 M phosphate buffer (pH = 7.4)
containing 0.2 M sucrose. The tissues were then postfixed for 2
hours at 4°C in 1% osmium tetroxide in 0.1 M phosphate buffer
(pH 7.4), dehydrated in ascending concentrations of ethanol
and embedded in Epon 812. Thick sections were stained with
toluidine blue and examined for routine orientation. Thin sec-
tions were stained with uranyl acetate and lead citrate, viewed
and photographed in a Philips EM 201 electron microscope.
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Months of study
Fig. 1. Monthly blood glucose profiles for the four animal groups.
Values are represented as mean SEM for each group. The symbols
are: (A) hyperglycemic diabetic rats, N = 8; •) euglycemic diabetic
rats, N = 5; (U) age—matched control rats, N = 7; and (•) streptozo-
tocin injected non-diabetic rats, N = 6. The blood glucose levels for the
hyperglycemic diabetic rats was significantly elevated (P < 0.05) over
the other three groups.
Quantification of kidney glomerular basement membrane was
performed utilizing the orthogonal intercept method of Jensen,
Gundersen and Osterby [301. The actual measurements were
carried out on micrographs (magnification x 20,000) with an
electronic planimeter (Hewlett Packard digitizer, model 9874A,
Elkhart, Indiana, USA) equipped with an electrosensitive cursor
connected to a Hewlett Packard 9875A calculator/computer.
The total number of micrographs assessed was 750. Glomerular
basement membrane thickness for each rat was measured on 25
randomly selected micrographs.
Statistics
The experimental data were analyzed by the unpaired t-test
to compare the means of the various groups. The level of
significance was P = 0.05. The statistical analysis was per-
formed on a commercial package (Crunch Interactic Statistics
Package [CRISP], Crunch Software, San Francisco, California,
USA). The statistical analysis for the morphological studies was
by ANOVA and Tukey's procedure [311.
Results
Metabolic and functional parameters
The mean, monthly blood—glucose levels for the four groups
of animals are shown in Figure 1. The hyperglycemic group had
a mean blood glucose level of 16.4 2.6 mmol/liter which was
significantly elevated (P < 0.05) over the other three groups;
namely age—matched controls, streptozotocin non-diabetics,
and diabetic euglycemics. There was no significant difference
between the mean blood—glucose levels of these latter three
Months of study
Fig. 2. Percent glycated hemoglobin profiles for the four animal groups in
the study. Values represent mean SD. The symbols are: (A) hyper-
glycemic diabetic rats, N = 8; (•) euglycemic diabetic rats, N = 5; (U)
age—matched control rats, N = 7; and (•) streptozotocin injected
non-diabetic rats, N = 6. The % glycated hemoglobin for the hypergly-
cemic diabetic rats was significantly elevated (P < 0.05) over the three
other groups at both 2 and 5 months of the study.
groups. Similarly, the hyperglycemic group had glycated hemo-
globin values which were significantly elevated (P <0.05) over
the other three groups of animals (Fig. 2).
The mean body weights of the diabetic hyperglycemic ani-
mals were 523 49 g, which was significantly decreased (P <
0.05) when compared to the three other groups. The kidney
weights of the diabetic hyperglycemic group was significantly
increased (P < 0.05) over that seen in the diabetic euglycemic,
age—matched controls, and streptozotocin non-diabetic ani-
mals, (Table 1). On the other hand, there were no statistical
differences among the latter three groups.
The mean glomerular filtration rate (GFR), as measured by
creatinine clearance for the four groups of animals, is summa-
rized in Figure 3. Diabetic hyperglycemic animals had an
elevated creatinine clearance (P < 0.05) at both 2 and 5 months
of the study over the three other groups. Moreover, creatinine
clearance when expressed in relation to kidney weight, was
significantly elevated (P < 0.05) at 5 months in the diabetic
hyperglycemic animals compared to the other three groups. In
addition, diabetic euglycemic, age—matched controls, and strep-
tozotocin non-diabetic groups had similar values at 2 and 5
months.
Urinary albumin excretion profiles for the various groups are
shown in Figure 4. The excretion rate appears age—dependent.
Moreover, the hyperglycemic diabetic animals had values sig-
nificantly elevated (P < 0.05) over the other three groups of
animals. Within each group there was a variable range of values
in albumin excretion. A correlation between the functional
results and the blood glucose levels was also found in our study;
blood glucose levels and GFR correlated directly (r = 0.68), as
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Table 1. Metabolic and functional results for diabetic and control animals at 5 months of study
Corrected
Average Kidney creatinine
blood weight mgi clearance
glucose % Glycated /00 g body mi/minig
Group Weight g mmoliliter hemoglobin wt kidney wt
Control N = 7 676 38 6.4 0.4 5.21 1.13 290 24 0.57 0.20
Drug control N = 6 657 66 5.9 0.6 6.42 0.79 281 28 0.53 0.20
Diabetic euglycemic
N = 5 668 58 7.0 0.5 4.65 0.61 304 29 0.50 0.24
Diabetic hyperglycemic
N = 8 523 49 16.4 2.6a 13.08 3.96a 421 69 1.02 0.36k'
Results are expressed as mean SD.
a P < 0.05 from the other groups
Fig. 3. Corrected crearinine clearance profiles for the four animal
groups of the study. The values represent mean SD except for the
diabetic hyperglycemic group in which only the means are listed due to
the large so's encountered. The symbols are: (A) hyperglycemic
diabetic rats, N = 8; (S) euglycemic diabetic rats, N = 5; (•)
age—matched control rats; N = 7; and (•) streptozotocin injected
non-diabetic rats, N = 6. The creatinine clearance for the hyperglyce-
mic rats was significantly (P < 0.05) elevated at both 2 and 5 months of
study.
did the percent of glycated hemoglobin and GFR (r =0.71). The
urinary albumin levels correlated to the blood glucose levels (r
= 0.63).
The functional and metabolic data at the completion of the
study is summarized in Table 1. The diabetic hyperglycemic
group differed with respect both to functional and metabolic
parameters when compared to the three other groups. In
contrast, the diabetic euglycemic group paralleled the control
and drug treated, non-diabetic animals with respect to these
parameters.
Biochemistry
The level of non-enzymatic glycation of glomerular basement
membrane isolated from the study animals at five months is
shown in Figure 5 and Table 2. The hyperglycemic diabetic
animals had significantly elevated values (P < 0.05) in compar-
ison to the other three groups. There was no statistical differ-
0 2 5
Months of study
Fig. 4. Urinary albumin excretion profiles for the four animal groups
of the study. The values represent mean SD, except for the diabetic
hyperglycemic group, in which only the means are listed due to the
large SD'S encountered. The symbols are: (A) hyperglycemic diabetic
rats, N = 8; (S) diabetic euglycemic rats, N = 5; (•) age—matched
control rats, N = 7; and (•) streptozotocin injected non-diabetic rats, N
= 6. The urinary albumin excretion for the hyperglycemic diabetic rats
was significantly elevated (P < 0.05) at both 2 and 5 months of study.
ence in non-enzymatic glycation among control and diabetic
euglycemic groups of animals. The level of non-enzymatic
glycation of glomerular basement membrane and average blood
glucose values correlated directly (r = 0.86) as shown in
Figure 6.
Morphology
The morphological data representing glomerular basement
membrane thickness, is shown in Table 3. All animals showed
an age dependent thickening over the course of the study. After
five months, the diabetic animals (both euglycemic and hyper-
glycemic) showed an increased (P < 0.05) in thickness over that
seen in the control groups of animals; however, there was no
statistical difference in glomerular basement membrane thick-
ening between the hyperglycemic or the euglycemic diabetic
animals.
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Fig. 5. The levels of non-enzymatic glycation of glomerular basement
membrane for the study rats in each group. The mean of each group is
represented by the horizontal bar.
Table 2. Non-enzymatic glycation of glomerular capillary basement
membrane
Level of non-enzymatic glycation
of glomerular basement
membrane cpm/ismol leucine
Group N equivalents
Control 7 351 203
Drug control 6 366 237
Diabetic euglycemic 5 468 182
Diabetic hyperglycemic 8 1260 52l
Non-enzymatic glycation of glomerular basement membrane
CPM/jmoI leucine equiv.
Fig. 6. The relationship between average glucose and the level of
non-enzymatic glycation of glomerular basement membrane.
Table 3. Morphometric analysis of glomerular basement membrane
thickenss in control and diabetic rats at 0 and 5 months of study
Basement membrane
Group thickness microns
Rats at time 0 0.085 0.005
Control at 5 months 0.197 0.009
Drug control at 5 months 0.191 0.009
Diabetic euglycemic at 5 months 0.217 0.Olla
Diabetic hyperglycemic at 5 months 0.220 0.0l7
Values represent SEM.
a P < 0,05 from other groups but not from each other
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Discussion
The etiology of diabetic nephropathy is unknown, but one
possible mechanism may be the result of hyperglycemia expe-
rienced in poorly controlled diabetics. The diabetic hypergly-
cemic animals of the present study exhibited elevated blood
glucose and percent glycated hemoglobin values over the other
three groups: namely the diabetic euglycemic, streptozotocin—
injected non-diabetic, and the age—matched control animals. In
contrast, the overall glycemic state of the diabetic euglycemic
animals paralleled that of the age—matched control and strepto-
zotocin non-diabetic animals.
The hyperglycemic diabetic animals also demonstrated an
elevation in the glomerular filtration rate (as measured by
creatinine clearance), as well as increased urinary albumin
excretion over the three other groups of animals. These changes
suggest that these animals were at an early stage of renal
impairment. The increase in the GFR of this group could be due
to several possible mechanisms. GFR has been shown to
increase with an increase in renal size [11], which was also
noted in the present study, subsequently leading to glomerular
enlargement and an increase in glomerular filtration area. The
Non-enzymatic glycation and renal function 669
role that hyperglycemia plays is uncertain; however, it may be
involved since strict glycemic control as evidenced in the
euglycemic diabetic animals was shown to prevent such an
increase. Furthermore, the correlation between glycated hemo-
globin levels and the GFR in the present study (r =0.71) would
support this. Another factor responsible for the changes ob-
served in the GFR may be hemodynamic rather than metabolic,
as suggested by Hostetter, Troy and Brenner [321. These
investigators noted that moderately hyperglycemic rats, that is,
blood glucose of 20 1.3 mmol/liter; levels similar to those in
our study, exhibited glomerular hyperfiltration resulting from
elevation in glomerular transcapillary hydraulic pressure and
glomerular plasma flow rate. In contrast, a reduction in GFR
was seen in severely hyperglycemic rats, that is, blood glucose
of 31 0.7 mmollliter due mainly to a fall in plasma flow rate.
The changes noted in the GFR were not affected by blood
volume, since this did not fluctuate among diabetic and control
animals. Moreover, in addition to the above, growth hormone,
angiotensin, and catecholamines may also be involved [33, 34].
Factors which can affect urinary albumin excretion include
the pore size of the basement membrane, which separates
molecules on the basis of their size, GFR and the net molecular
charge of the membrane. In the present study, it is unlikely that
pore size played a role, since only in late stages of diabetes do
such changes occur [35]. Therefore, the increased GFR ob-
served and changes in glomerular basement membrane charge
may be involved in the increased urinary albumin excretion
rates seen in the hyperglycemic animals.
It has previously been shown that increased levels of non-
enzymatic glycation of protein in diabetics can lead to structural
and functional changes including changes in net charge [4, 81.
The increased level of non-enzymatic glycation of glomerular
basement membrane, as shown in this study, may result in
similar changes. The removal of the positive charge on hydroxy-
lysine by non-enzymatic glycation may prevent interchain
crosslinking [36] of type IV collagen, the major component of
glomerular basement membrane; this could interfere with the
packing of the collagen fibrils, resulting in increased pore size
and increased membrane permeability. This change in charge
subsequent to non-enzymatic glycation is supported by the
work of Schober et al [37], who have shown that the im-
munoelectrophoretic pattern of in vitro glycated membranes
was different from that of native basement membrane. The
charge relationship between the glomerular basement mem-
brane and a protein in question is important in the passage of
molecules through the filtration barrier [38]. The negative
charge of the glomerular basement membrane will normally
repel the passage of negatively charged proteins, such as
albumin, and facilitate the passage of neutral and especially
cationic ones [36]. The non-enzymatic glycation of albumin can
be expected to increase its anionic nature, further repelling its
passage. However, due to its relatively short half—life (<30
days) in comparison to that of glomerular basement membrane,
it can be expected that it will not be glycated to the same extent
as the latter. This could change its charge relationship with
glomerular basement membrane such that albumin will have an
increased net positive charge. This could result in increased
passage of albumin through the filtration barrier, resulting in
microalbuminuria.
Another interesting finding was that there was no difference
in glomerular basement membrane—thickness between the eu-
glycemic and the hyperglycemic diabetic animals, despite the
fact that these groups exhibited differences in renal function and
in the extent of non-enzymatic glycation. Our data therefore
suggests that basement membrane thickening per se may not be
important in the development of diabetic nephropathy. This is
consistent with the work of Mauer et al [15] which suggested
that mesangial expansion rather than glomerular basement
membrane—thickening leads to glomerular functional deteriora-
tion in diabetes by restricting the glomerular capillary vascula-
ture and its filtration surface. Moreover, factors other than
hyperglycemia have also been shown to be associated with
increased, glomerular basement membrane—thickness. Systemic
lupus erythematosus (SLE) results in the formation of anti-
DNA antibody—antigen complexes, which become lodged in the
filtration barrier causing the appearance of increased GBMT
when viewed with the electron microscope [39]. Besides im-
mune complexes, antibodies directed against the glomerular
basement membrane itself have been observed to result in
glomerular basement membrane—thickening, as in the case of
Goodpasture's syndrome [40]. In addition, non-disease states
such as ageing, as was seen in the present study, appear
associated with increased basement membrane—thickening. This
was noted in the age matched controls which had a significant
increase in basement membrane thickening, without compro-
mise in renal function, over the time—zero control animals.
We have shown changes in renal function, increased GFR
and increased urinary albumin excretion, without changes in
glomerular basement membrane—thickness, which suggests and
supports evidence that the latter may not be important in the
renal changes associated with diabetic nephropathy. Hypergly-
cemia appears to be involved in some way in the development
of renal functional changes, however, its exact role is unknown.
The increased level of non-enzymatic glycation that results
from hyperglycemia may be responsible for the alteration of
glomerular basement membrane, ultimately resulting in renal
functional impairment and the future development of chronic
diabetic nephropathy. It is therefore important that diabetics
are maintained under good glycemic control to prevent the
development of diabetic nephropathy.
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